Ian Lane ^{Ultimate Decision-Maker}

Partner at Cambridge Innovation Capital

Current Job Duration: 4 yrs 9 mos (until March 2026)

HEADLINE:
Partner at Cambridge Innovation Capital

PERSONAL SUMMARY:
Ian is a DeepTech Partner at CIC, focussing on AI, Future of Compute, Robotics and Quantum. Ian manages CIC’s investments into Salience, Cytora (acquired by Applied), Seldon, Cambridge GaN Devices, Unlikely AI and Secondmind.

Before joining CIC Ian was a Director at Unilever Ventures in London, where he led B2B/Technology direct investments and managed a portfolio of fund LP positions. Over 11 years he was responsible for direct investments across Europe and North America, including Olapic (acquired by Monotype Inc), Celtra (acquired by STG), Blis Global (acquired by LDC), Discuss (acquired by Voxco), Skupos (acquired by PDI Technologies), Runa, Mirakl, Aera Technology, CreatorIQ and Mirriad (Listed on AIM). As a fund-of-funds manager, Ian worked closely with a range of GP's including managers at Stride, Cathay Innovation and Ahren Innovation Capital.

Prior to Unilever Ventures, Ian worked at L.E.K. Consulting in London and Australia, working on strategy consulting and private equity due-diligence projects.

Ian has PhD in Physical Chemistry from the University of Cambridge and Msci in Chemistry from Bristol University.

Languages:

EDUCATION:
School: University of Cambridge
Degree: PhD, Chemistry / Physics
Activities: None

School: University of Bristol
Degree: Msci, Chemsitry
Activities: None

Number of Followers:
4447